Hôtel-Dieu de Québec
11 Côte du Palais, bureau 1167
Canada G1R 2J6
Information non disponible
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trialsArticle de revue
Cancer, 125 (12), 2019.
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129Article de revue
Int J Radiat Oncol Biol Phys, 97 (4), 2017.
Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled TrialArticle de revue
Ann Otol Rhinol Laryngol, 125 (4), 2016.
A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathwaysArticle de revue
Cancer Epidemiol, 42 , 2016.
Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129Article de revue
Int J Radiat Oncol Biol Phys, 96 (2), 2016.
Regional Nodal Irradiation in Early-Stage Breast CancerArticle de revue
N Engl J Med, 373 (4), 2015.
Institutional clinical trial accrual volume and survival of patients with head and neck cancerArticle de revue
J Clin Oncol, 33 (2), 2015.
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trialArticle de revue
Lancet Oncol, 16 (2), 2015.
The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trialArticle de revue
Qual Life Res, 23 (6), 2014.
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicityArticle de revue
J Clin Oncol, 32 (34), 2014.